Chest:阿瑞匹坦作为晚期肺癌的咳嗽抑制剂

2020-01-18 xiangting MedSci原创

阿瑞匹坦使得晚期肺癌患者的咳嗽得到明显改善,并且不增加严重副作用。

尽管咳嗽是肺癌患者常见和令人痛苦的症状,但几乎没有证据可以指导治疗。在一项试点研究中阿瑞匹坦(一种中枢作用的神经激肽-1抑制剂)明显降低咳嗽频率。

尽管使用止咳药,但咳嗽仍持续超过2周的晚期肺癌患者按照11比例被随机分至阿瑞匹坦组或仅使用医师自行选择的镇咳药组。阿瑞匹坦组第1天口服125 mg,然后第2天至第7天口服80 mg,并同时使用医师自行选择的镇咳药。在基线以及第37912天进行评估。主要终点是第9天的主观咳嗽改善,通过视觉模拟量表(VAS)和曼彻斯特肺癌咳嗽量表(MCLCS)进行测量。次要终点包括通过EORTC QLQ-C30QLQ-LC13测量的生活质量(QoL)和毒性。

2017年至2018年间,128例患者被随机分配。基线咳嗽持续时间中位数为90天。阿瑞匹坦组基线和第9天的平均VAS评分(in mm)分别为6839,而对照组为6249P<0.001;阿瑞匹坦组基线和第9天的平均MCLCS评分为3323,而对照组为3025P<0.001。两组间的总体QoL并无显著差异,但是阿瑞匹坦使得咳嗽特异性QoL领域明显改善,P=0.017。阿瑞匹坦并未增加严重不良事件。

阿瑞匹坦使得晚期肺癌患者的咳嗽得到明显改善,并且不增加严重副作用。

原始出处:

Vanita Noronha. Aprepitant for Cough Suppression in Advanced Lung Cancer: A Randomized Trial. Chest. 17 January 2020.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1929608, encodeId=0615192960828, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sat Jun 20 07:24:00 CST 2020, time=2020-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852252, encodeId=67a51852252cf, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Nov 07 08:24:00 CST 2020, time=2020-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051497, encodeId=e787205149ede, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sun Nov 15 03:24:00 CST 2020, time=2020-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630950, encodeId=5ee31630950b7, content=<a href='/topic/show?id=ca8259866b6' target=_blank style='color:#2F92EE;'>#晚期肺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59866, encryptionId=ca8259866b6, topicName=晚期肺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=974321610743, createdName=yangwen5716, createdTime=Mon Jan 20 03:24:00 CST 2020, time=2020-01-20, status=1, ipAttribution=)]
    2020-06-20 Smile2680
  2. [GetPortalCommentsPageByObjectIdResponse(id=1929608, encodeId=0615192960828, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sat Jun 20 07:24:00 CST 2020, time=2020-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852252, encodeId=67a51852252cf, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Nov 07 08:24:00 CST 2020, time=2020-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051497, encodeId=e787205149ede, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sun Nov 15 03:24:00 CST 2020, time=2020-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630950, encodeId=5ee31630950b7, content=<a href='/topic/show?id=ca8259866b6' target=_blank style='color:#2F92EE;'>#晚期肺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59866, encryptionId=ca8259866b6, topicName=晚期肺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=974321610743, createdName=yangwen5716, createdTime=Mon Jan 20 03:24:00 CST 2020, time=2020-01-20, status=1, ipAttribution=)]
    2020-11-07 jklm09
  3. [GetPortalCommentsPageByObjectIdResponse(id=1929608, encodeId=0615192960828, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sat Jun 20 07:24:00 CST 2020, time=2020-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852252, encodeId=67a51852252cf, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Nov 07 08:24:00 CST 2020, time=2020-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051497, encodeId=e787205149ede, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sun Nov 15 03:24:00 CST 2020, time=2020-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630950, encodeId=5ee31630950b7, content=<a href='/topic/show?id=ca8259866b6' target=_blank style='color:#2F92EE;'>#晚期肺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59866, encryptionId=ca8259866b6, topicName=晚期肺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=974321610743, createdName=yangwen5716, createdTime=Mon Jan 20 03:24:00 CST 2020, time=2020-01-20, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1929608, encodeId=0615192960828, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sat Jun 20 07:24:00 CST 2020, time=2020-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852252, encodeId=67a51852252cf, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Nov 07 08:24:00 CST 2020, time=2020-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051497, encodeId=e787205149ede, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sun Nov 15 03:24:00 CST 2020, time=2020-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630950, encodeId=5ee31630950b7, content=<a href='/topic/show?id=ca8259866b6' target=_blank style='color:#2F92EE;'>#晚期肺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59866, encryptionId=ca8259866b6, topicName=晚期肺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=974321610743, createdName=yangwen5716, createdTime=Mon Jan 20 03:24:00 CST 2020, time=2020-01-20, status=1, ipAttribution=)]

相关资讯

Cell Death Dis:间充质干细胞通过扩增MDSCs促进癌细胞存活转移

骨髓间充质干细胞(BMSCs)是一种能分化成多种细胞类型的多能基质干细胞。 BMSCs在化学指导下作用于癌细胞,并促进癌细胞微环境的形成。 BMSC的归巢受到多种因素的影响。远处器官(特别是骨髓)扩散的肿瘤细胞(DTCs)是癌症转移和复发的来源。 DTC的存活取决于微环境。在本研究中,研究人员旨在阐明受癌症改造的BMSCs是如何促进癌细胞在原发肿瘤部位和远处存活的。研究人员通过肿瘤内BMSCs和返

Sci Rep:他汀类药物通过p53突变介导的细胞凋亡对肺腺癌有疗效

这些数据表明,在某些肺癌患者中使用他汀类药物具有临床益处。

Sci Rep:ONECUT2过表达促进RAS驱动的肺腺癌进展

由正常沉默的组织-特异性基因激活驱动的异常分化导致细胞身份的转换,并通常导致癌症的进展。潜在的遗传和表观遗传学改变在很大程度上仍然未知。这里报告了肝胆、肠和神经特异性基因onecuthomeobox2(ONECUT2)在肺癌不同亚型中的异位激活。   ONECUT2表达与RAS驱动的肺腺癌预后不良相关。ONECUT2过表达在体外促进肿瘤生长和A549肺癌细胞的侵袭,在体内促进

张力:2019年肺癌免疫治疗年终盘点

方文峰,张力(中山大学肿瘤防治中心  内科,广州  510060) 【摘要】 免疫治疗的蓬勃发展为驱动基因阴性的患者带来了希望,肺癌的治疗格局正在经历革命性变革。笔者通过梳理2019年肺癌免疫治疗的研究报道,总结为下述6方面:①长生存:驱动基因阴性的非小细胞肺癌患者接受免疫单药二线治疗的5年生存率约为15%,一线治疗的5年生存率为23.2%,其中高表达程序性死亡蛋白配

NEJM:确诊9个月后死亡!这种皮疹极易误诊

看到皮疹,我们一般首先想的是皮肤科,但是,有时候皮疹的背后可能隐藏着呼吸科的严重问题。究竟什么情况下,皮疹要查肺癌呢?《新英格兰医学杂志》(NEJM)的这个病例会给我们很多启发。

Sci Rep:非小细胞肺癌中IL-1β诱导的慢性炎症通过表观遗传修饰调节EMT记忆表型

化学抑制DNA甲基化不仅可以恢复EMT记忆的上皮钙粘蛋白表达,还可以引发化疗诱导的细胞凋亡。